R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study

Overview of attention for article published in Blood, November 2024

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (76th percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

patent: 2 patents

Readers on

mendeley: 2 Mendeley

So far, Altmetric has seen 2 patents that reference this research output.

IRAK INHIBITOR FOR THE TREATMENT OF A MYELODISPLASTIC SYNDROME

Application WO-2026122127-A1

World Intellectual Property Organisation (WIPO)

COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME

Application US-20220249475-A1

United States of America

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity.